ArticleMolecular nutrition & food research2026
Targeting Senescence: Tianma Granule Inhibits Colorectal Cancer Progression by Modulating miR-29a-5p/P53 Signaling in the Tumor Microenvironment.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Senescence: Tianma Granule Inhibits Colorectal Cancer Progression by Modulating miR-29a-5p/P53 Signaling in the Tumor Microenvironment.Molecular nutrition & food research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chemotherapy-induced senescence-associated tumor microenvironment (S-TME) facilitates colorectal cancer (CRC) progression. This study elucidates the mechanism by which Tianma granule (TMG), a traditional Chinese medicine formula, remodels the S-TME and inhibits CRC, specifically investigating the role of the miR-29a-5p/P53 axis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified 18 bioactive components in TMG, and network pharmacology highlighted P53 as a core target. Functional assays, including Cell Counting Kit-8 (CCK-8), β-galactosidase staining, flow cytometry, wound-healing, and Transwell migration tests, were conducted using doxorubicin (DOX)-induced senescent human umbilical vein endothelial cells (HUVECs) and CRC lines. TMG suppressed CRC cell proliferation, motility, and invasiveness while promoting apoptosis. TMG reduced P53/cyclin-dependent kinase inhibitor 1A (P21) and senescence-associated secretory phenotype (SASP) factors (IL-6, IL-8, CCL20), while upregulating miR-29a-5p in senescent HUVECs. miR-29a-5p inhibition enhanced senescence and increased P53/P21/SASP, whereas P53 silencing lowered P21 and decreased miR-29a-5p, indicating mutual regulation. In azoxymethane/dextran sulfate sodium (AOM/DSS)-CRC mice, TMG reduced tumor burden and improved survival, accompanied by lower P53/P21 and restored miR-29a-5p in tissues. TMG remodels the chemotherapy-induced S-TME and suppresses CRC progression by modulating the miR-29a-5p/P53 axis, enhancing apoptosis in senescent cells, and counteracting S-TME-mediated tumor growth and metastasis. This highlights TMG's therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.